Interactive Clinical Discussion on XPOVIO
XPOVIO® (selinexor) The first and only FDA-approved oral selective nuclear export inhibitor in relapsed refractory multiple myeloma (RRMM)
Virtual Event through Adobe Connect
Joseph Mikhael, MD
Translational Genomics Research Institute (City of Hope)
To RSVP, please email KaryopharmRSVP@PW.Veeva.com or call 866-914-9069
Please Note: You will receive log-in/dial-in details once you are successfully registered
KAR0000856 Please reference this number during registration.